Literature DB >> 6799680

Comparison of serum blocking factors on leucocyte adherence inhibition and PHA lymphocyte blastogenesis in breast cancer patients.

T Fujisawa, R H Yonemoto, S R Waldman.   

Abstract

Specific and nonspecific serum blocking factors (SBF) in sera from 48 breast cancer patients were examined to evaluate the correlation of SBF to the tumor burden. Specific SBF in leucocyte adherence inhibition (LAI) assay was demonstrated in 15 of 21 patients with a recurrence, in five of 11 with local or regional involvement and in 3 of 16 with no evidence of the disease (NED). The difference between patients with recurrence and with NED was significant (P less than 0.005). SBF in LAI and lymphocyte blastogenesis correlated in 29 of 48 (60%) patients (both positive 9 of 48, both negative 20 of 48). However, SBF in LAI was demonstrated in 14 of 48 (29%) patients whose sera showed no SBF in lymphocyte blastogenesis. These results indicate that SBF in LAI and lymphocyte blastogenesis are either induced or derived from breast cancer tissue. SBF in LAI correlates closely with the tumor burden, more so than do SBF in lymphocyte blastogenesis. The blocking assays have a potential use for prognostication and a guide for clinical therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6799680     DOI: 10.1007/BF02469023

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  20 in total

1.  On the nature of blocking factors and their lymphoid target cells in an allogeneic tumor system.

Authors:  A Mantovani; F Spreafico
Journal:  Eur J Cancer       Date:  1975-06       Impact factor: 9.162

2.  Tumor-associated blocking factors: isolation from sera of tumor-bearing mice.

Authors:  J Tamerius; J Nepom; I Hellström; K E Hellström
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

3.  Tumor-specific antigen solubilized by hypertonic potassium chloride.

Authors:  M S Meltzer; E J Leonard; H J Rapp; T Borsos
Journal:  J Natl Cancer Inst       Date:  1971-09       Impact factor: 13.506

4.  Leukemic serum inhibition of phytohemagglutinin-induced transformation.

Authors:  G B Humphrey; J Lankford; S Oleinick; R Nitschke
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

5.  Cell-mediated immunity and specific serum factors in human cancer: the leukocyte adherence inhibition test.

Authors:  A Maluish; W J Halliday
Journal:  J Natl Cancer Inst       Date:  1974-05       Impact factor: 13.506

6.  Cell-mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma.

Authors:  G H Heppner; L Stolbach; M Byrne; F J Cummings; E McDonough; P Calabresi
Journal:  Int J Cancer       Date:  1973-03-15       Impact factor: 7.396

7.  Separation of leukocytes from blood and bone marrow. Introduction.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

8.  Effect of serum blocking factors on leukocyte adherence inhibition in breast cancer patients: specificity and correlation with tumor burden.

Authors:  R H Yonemoto; T Fujisawa; S R Waldman
Journal:  Cancer       Date:  1978-04       Impact factor: 6.860

9.  Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms.

Authors:  I Hellström; H O Sjögren; G Warner; K E Hellström
Journal:  Int J Cancer       Date:  1971-03-15       Impact factor: 7.396

10.  Lymphocyte reactivity in cancer patients: correlation with tumor histology and clinical stage.

Authors:  W J Catalona; W F Sample; P B Chretien
Journal:  Cancer       Date:  1973-01       Impact factor: 6.860

View more
  1 in total

1.  Transfer factor in restoration of cell mediated immunity in lung cancer patients.

Authors:  T Fujisawa; Y Yamaguchi; H Kimura
Journal:  Jpn J Surg       Date:  1983-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.